{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:08:48Z","timestamp":1774393728468,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.beha.2004.03.008","type":"journal-article","created":{"date-parts":[[2004,5,31]],"date-time":"2004-05-31T15:09:05Z","timestamp":1086016145000},"page":"127-138","source":"Crossref","is-referenced-by-count":26,"title":["Small-molecule direct antithrombins: argatroban"],"prefix":"10.1016","volume":"17","author":[{"given":"Jawed","family":"Fareed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter P","family":"Jeske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2004.03.008_BIB1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-0038-1642724","article-title":"Comparative pharmacology of site directed antithrombin agents. Implication in drug development","volume":"74","author":"Callas","year":"1995","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-2007-1000393","article-title":"Comparative studies on the anticoagulant and protease generation inhibitory actions of newly-developed site-directed thrombin inhibitory drugs","volume":"21","author":"Callas","year":"1995","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-2007-1002783","article-title":"Regulation of thrombin generation and functions","volume":"14","author":"Fenton","year":"1988","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB4","first-page":"233","article-title":"Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin","volume":"22","author":"Lunven","year":"1996","journal-title":"Thrombosis and Hemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1527-3466.1991.tb00415.x","article-title":"Argatroban, a selective, potent thrombin inhibitor","volume":"9","author":"Bush","year":"1991","journal-title":"Cardiovascular Drug Reviews"},{"key":"10.1016\/j.beha.2004.03.008_BIB6","doi-asserted-by":"crossref","first-page":"20085","DOI":"10.1016\/S0021-9258(18)54894-8","article-title":"Crystallographic analysis at 3.0 A resolution of the binding to human thrombin and four active site-directed inhibitors","volume":"266","author":"Banner","year":"1991","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.beha.2004.03.008_BIB7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/bi00296a014","article-title":"Selective inhibition of thrombin by (2R, 4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperidinecarboxylic acid","volume":"23","author":"Kikumoto","year":"1984","journal-title":"Biochemistry"},{"key":"10.1016\/j.beha.2004.03.008_BIB8","first-page":"1","article-title":"Antithrombin effect of a new synthetic thrombin inhibitor, MD 805, on blood coagulation","volume":"2","author":"Nagasawa","year":"1981","journal-title":"Biomedical Sciences"},{"key":"10.1016\/j.beha.2004.03.008_BIB9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/107602960300900403","article-title":"Influence of different anticoagulant agents on fibrinopeptide a generation","volume":"9","author":"Tobu","year":"2003","journal-title":"Clinical and Applied Thrombosis and Hemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","article-title":"Effects of the sythetic thrombin inhibitor argatroban on fibrin-or-clot-incorporated thrombin: comparison with heparin and recombinant hirudin","volume":"72","author":"Berry","year":"1994","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB11","first-page":"2677","article-title":"Effects of newly synthesized antithrombin agent (MD-805) on blood coagulation system","volume":"40","author":"Niwa","year":"1985","journal-title":"Saishin Igaku"},{"key":"10.1016\/j.beha.2004.03.008_BIB12","first-page":"7","article-title":"Effect of argatroban on blood coagulation","volume":"14","author":"Tamao","year":"1986","journal-title":"Japanese Journal of Pharmaceutical Therapy"},{"key":"10.1016\/j.beha.2004.03.008_BIB13","first-page":"1366","article-title":"Direct thrombin inhibitors: appraisal of the antithrombotic\/hemorrhagic balance","volume":"78","author":"Verstraete","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"issue":"supplement 3","key":"10.1016\/j.beha.2004.03.008_BIB14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000069110","article-title":"Practical issues in the development of argatroban: a perspective","volume":"32","author":"Fareed","year":"2002","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"key":"10.1016\/j.beha.2004.03.008_BIB15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00129784-200303030-00006","article-title":"New anticoagulants; current status and future potential","volume":"3","author":"Weitz","year":"2003","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1016\/j.beha.2004.03.008_BIB16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/13543784.8.5.625","article-title":"Pharmacology of argatroban","volume":"8","author":"Jeske","year":"1999","journal-title":"Expert Opinion in Investigative Drugs"},{"key":"10.1016\/j.beha.2004.03.008_BIB17","first-page":"500a","article-title":"Differential effects of argatroban and heparin on Hemochron and Hemo-tec activated clotting times in patients undergoing coronary interventional procedures","volume":"29","author":"Hursting","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.008_BIB18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","article-title":"Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin","volume":"72","author":"Berry","year":"1994","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0038-1650236","article-title":"Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-asociated thrombin","volume":"75","author":"Lunven","year":"1996","journal-title":"Thrombosis and Haemostasis"},{"issue":"supplement 4","key":"10.1016\/j.beha.2004.03.008_BIB20","first-page":"70","article-title":"Modulating platelet function with selective thrombin inhibitors","volume":"26","author":"Verstraete","year":"1996","journal-title":"Haemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB21","first-page":"271","article-title":"Inhibition of thrombin-induced platelet adherance to vascular cells by synthetic thrombin inhibitor no 805","volume":"96","author":"Czervionke","year":"1983","journal-title":"Transactions of the Association of American Physicists"},{"key":"10.1016\/j.beha.2004.03.008_BIB22","first-page":"141","article-title":"Changes of rabbit platelet function following simultaneous administration of ticlopidine hydrochloride and argipidone (MD-805)","volume":"14","author":"Kosugi","year":"1992","journal-title":"International Journal of Tissue Reactions"},{"key":"10.1016\/j.beha.2004.03.008_BIB23","first-page":"125","article-title":"Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury","volume":"101","author":"Eidt","year":"1988","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2004.03.008_BIB24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0049-3848(85)90309-3","article-title":"Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitor","volume":"40","author":"Nakamura","year":"1985","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.beha.2004.03.008_BIB25","first-page":"2561","article-title":"Therapeutic evaluation of recombinant thrombomodulin","volume":"50","author":"Maruyama","year":"1992","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.beha.2004.03.008_BIB26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1476-5381.1994.tb17126.x","article-title":"Antithrombotic actions of argatroban in rat models of venous, \u2018mixed\u2019 and arterial thrombosis, and its effects on the tail transection bleeding time","volume":"113","author":"Berry","year":"1994","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.beha.2004.03.008_BIB27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/107602969500100203","article-title":"Fibrinolytic compromise by synthetic and recombinant thrombin inhibitors: implications in the treatment of thrombotic disorders","volume":"1","author":"Callas","year":"1995","journal-title":"Clinical and Applied Thrombosis and Hemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1051-0443(95)71067-3","article-title":"Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental animals","volume":"6","author":"Valji","year":"1995","journal-title":"Journal of Vascular and Interventional Radiology"},{"key":"10.1016\/j.beha.2004.03.008_BIB29","first-page":"329","article-title":"Prevention of rethrombosis after thrombolysis by synthetic thrombin inhibitor argipidine (MD 805)","volume":"62","author":"Eisert","year":"1989","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB30","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1253\/jcj.56.1184","article-title":"Experimental evaluation of coronary thrombodynamics and effects of pharmacological interventions in acute coronary syndromes","volume":"56","author":"Tomodo","year":"1992","journal-title":"Japanese Circulation Journal"},{"key":"10.1016\/j.beha.2004.03.008_BIB31","first-page":"165","article-title":"Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits","volume":"37","author":"Hara","year":"1987","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB32","first-page":"409","article-title":"Clinical evaluation of synthetic thrombin inhibitor MD-805 in disseminated intravascular coagulation (DIC)","volume":"6","author":"Maekawa","year":"1987","journal-title":"Therapeutic Research"},{"key":"10.1016\/j.beha.2004.03.008_BIB33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0049-3848(91)90140-R","article-title":"Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats","volume":"63","author":"Morishita","year":"1991","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.beha.2004.03.008_BIB34","first-page":"1377","article-title":"Experimental extracorporeal circulation with a synthetic thrombin inhibitor, MD-805, without heparin","volume":"31","author":"Matsukura","year":"1983","journal-title":"Journal of Japanese Association for Thoracic Surgery"},{"key":"10.1016\/j.beha.2004.03.008_BIB35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","article-title":"The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.beha.2004.03.008_BIB36","first-page":"865","article-title":"Clinical report on the treatment of antithrombin MD-805","volume":"6","author":"Higuchi","year":"1987","journal-title":"Therapeutic Research"},{"key":"10.1016\/j.beha.2004.03.008_BIB37","first-page":"2347","article-title":"Therapeutical effect of MD-805, a synthetic antithrombin drug, on disseminated intravascular coagulation","volume":"23","author":"Higuchi","year":"1986","journal-title":"Medical Consultant for New Drugs"},{"key":"10.1016\/j.beha.2004.03.008_BIB38","first-page":"1754","article-title":"Effect of MD-805, a synthetic thrombin inhibitor, on disseminated intravascular coagulation development on hematologic disorders","volume":"26","author":"Higuchi","year":"1985","journal-title":"Japanese Journal of Clinical Hematology"},{"key":"10.1016\/j.beha.2004.03.008_BIB39","first-page":"353","article-title":"Experiences of treatment of DIC with thrombin inhibitor MD-805 after cardiovascular surgery","volume":"7","author":"Kumon","year":"1987","journal-title":"Progress in Medicine (Japan)"},{"key":"10.1016\/j.beha.2004.03.008_BIB40","first-page":"2208","article-title":"The effect of synthetic thrombin inhibitor MD-805 on DIC before and after cardiovascular surgery","volume":"71","author":"Kumon","year":"1983","journal-title":"Diagnostic and Treatment"},{"key":"10.1016\/j.beha.2004.03.008_BIB41","first-page":"409","article-title":"Clinical evaluation of synthetic thrombin inhibitor MD-805 in disseminated intravascular coagulation (DIC)","volume":"6","author":"Maekawa","year":"1987","journal-title":"Therapeutic Research"},{"key":"10.1016\/j.beha.2004.03.008_BIB42","first-page":"35","article-title":"Experience of using MD-805 in one case with DIC complicated with pneumonia","volume":"37","author":"Niikura","year":"1992","journal-title":"Haemostasis"},{"key":"10.1016\/j.beha.2004.03.008_BIB43","first-page":"171","article-title":"Studies on effects of MD-805 of DIC","volume":"36","author":"Sugishima","year":"1987","journal-title":"Journal of the New Remedial Clinic"},{"key":"10.1016\/j.beha.2004.03.008_BIB44","first-page":"811","article-title":"Beneficial use of argatroban in DIC","volume":"23","author":"Yamada","year":"1982","journal-title":"Clinical Hematology"},{"key":"10.1016\/j.beha.2004.03.008_BIB45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00001721-199507000-00008","article-title":"Thrombin inhibition in the acute phase of ischaemic stroke using argatroban","volume":"6","author":"Kario","year":"1995","journal-title":"Blood Coagulation & Fibrinolysis"},{"key":"10.1016\/j.beha.2004.03.008_BIB46","first-page":"251","article-title":"The effect of an antithrombin agent, MD 805, which acts selectively on progressive cerebral thrombosis: comparison with that of urokinase therapy","volume":"63","author":"Kitani","year":"1986","journal-title":"Clinical Research"},{"key":"10.1016\/j.beha.2004.03.008_BIB47","first-page":"9041","article-title":"Clinical effects of the antithrombin drug, MD 805, on acute cerebral thrombosis\u2014clinical study in early phase II","volume":"20","author":"Tazaki","year":"1986","journal-title":"Japanese Pharmaceutical Therapy (Kiso to Rinsho)"},{"key":"10.1016\/j.beha.2004.03.008_BIB48","first-page":"803","article-title":"Left heart bypass with the bio-medicus centrifugal pump by the use of an antithrombin agent, argatroban","volume":"47","author":"Kawada","year":"1994","journal-title":"Kyobu Geka"},{"key":"10.1016\/j.beha.2004.03.008_BIB49","first-page":"185A","article-title":"Intravenous argatroban versus heparin as co-medication to alteplase in the treatment of acute myocardial infarction; preliminary results of the ARGAMI pilot study","volume":"29","author":"Vermeer","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.008_BIB50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0049-3848(95)93840-V","article-title":"Effect of argatroban on thrombus formation during acute coronary occlusion after balloon angioplasty","volume":"77","author":"Suzuki","year":"1995","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.beha.2004.03.008_BIB51","first-page":"359","article-title":"Phase one study of synthetic antithrombin agent (MD-805). Single and multiple administration studies","volume":"12","author":"Nagasawa","year":"1981","journal-title":"Japanese Journal of Pharmaceutical Therapy"},{"issue":"supplement 5","key":"10.1016\/j.beha.2004.03.008_BIB52","first-page":"251","article-title":"Pharmacokinetics studies of argatroban (MD-805) in human\u2014concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion","volume":"14","author":"Izawa","year":"1986","journal-title":"Japanese Journal of Pharmaceutical Therapy"},{"key":"10.1016\/j.beha.2004.03.008_BIB53","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.008_BIB54","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.008_BIB55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ccd.10276","article-title":"Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin induced thrombocytopenia","volume":"57","author":"Lewis","year":"2002","journal-title":"Catheterization and Cardiovascular Interventions"},{"key":"10.1016\/j.beha.2004.03.008_BIB56","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1213\/01.ANE.0000052381.47101.A2","article-title":"Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation","volume":"96","author":"Kieta","year":"2003","journal-title":"Anesthesia and Analgesia"},{"key":"10.1016\/j.beha.2004.03.008_BIB57","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0003-4975(02)04782-3","article-title":"Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient","volume":"75","author":"Edwards","year":"2003","journal-title":"The Annals of Thoracic Surgery"},{"key":"10.1016\/j.beha.2004.03.008_BIB58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s003800300006","article-title":"Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary artery bypass","volume":"18","author":"Ohno","year":"2003","journal-title":"Heart and Vessels"},{"key":"10.1016\/j.beha.2004.03.008_BIB59","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1213\/01.ANE.0000077655.77618.B7","article-title":"Argatroban for off-pump coronary artery bypass surgery","volume":"97","author":"Green","year":"2003","journal-title":"Anesthesia and Analgesia"},{"issue":"supplement 1","key":"10.1016\/j.beha.2004.03.008_BIB60","first-page":"453","article-title":"Argatroban versus heparin as adjuvant therapy for thrombolysis for acute myocardial infarction: safety considerations ARGAMI-1 study","volume":"98","author":"Behar","year":"1998","journal-title":"Circulation"},{"issue":"supplement","key":"10.1016\/j.beha.2004.03.008_BIB61","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular weight heparin. Sixth ACCP consensus conference on antithrombotic therapy","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692604000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692604000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T18:37:51Z","timestamp":1624387071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692604000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S1521692604000118"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2004.03.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}